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abstract
PURPOSE To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH)
recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.
METHODS PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-
analyses of RCTs in patients with cancer published from January 31, 2010, through May 14, 2018. For
biosimilar ESAs, the literature search was expanded to include meta-analyses and RCTs in patients with cancer
or chronic kidney disease and cohort studies in patients with cancer due to limited RCT evidence in the cancer
setting. ASCO and ASH convened an Expert Panel to review the evidence and revise previous recommendations
as needed.
RESULTS The primary literature review included 15 meta-analyses of RCTs and two RCTs. A growing body of
evidence suggests that adding iron to treatment with an ESA may improve hematopoietic response and reduce
the likelihood of RBC transfusion. The biosimilar literature review suggested that biosimilars of epoetin alfa have
similar efﬁcacy and safety to reference products, although evidence in cancer remains limited.
RECOMMENDATIONS ESAs (including biosimilars) may be offered to patients with chemotherapy-associated
anemia whose cancer treatment is not curative in intent and whose hemoglobin has declined to, 10 g/dL. RBC
transfusion is also an option. With the exception of selected patients with myelodysplastic syndromes, ESAs
should not be offered to most patients with nonchemotherapy-associated anemia. During ESA treatment,
hemoglobin may be increased to the lowest concentration needed to avoid transfusions. Iron replacement may
be used to improve hemoglobin response and reduce RBC transfusions for patients receiving ESAwith or without
iron deﬁciency. Additional information is available at www.asco.org/supportive-care-guidelines and www.
hematology.org/guidelines.
J Clin Oncol 37. © 2019 by American Society of Clinical Oncology
INTRODUCTION
Use of erythropoiesis-stimulating agents (ESAs) to
manage anemia raises hemoglobin (HgB) levels and
reduces the need for RBC transfusions, but increases
the risk of thromboembolic events.1,2 Studies have also
reported decreased survival, increased mortality dur-
ing active study phase, and/or an increased risk of
cancer progression or recurrence with the use of ESAs
in patients with cancer.3-6 The risks of ESAs prompted
multiple regulatory actions by the US Food and Drug
Administration (FDA) between 2004 and 2009, and in
2010, the FDA approved a Risk Evaluation and Miti-
gation Strategy for ESA use in patients with cancer. In
2017, the FDA determined that the Risk Evaluation
and Mitigation Strategy was no longer necessary:
prescribers demonstrated acceptable knowledge of
the risks of ESAs and the need to counsel patients
about the risks, and utilization data suggested an
increase in appropriate prescribing practices.7 The risks
of ESAs remain, however, highlighting the ongoing
importance of appropriate use. ESAs are indicated in
patients with cancer who are receiving myelosup-
pressive chemotherapy with noncurative intent and
anemia that cannot be adequately managed with
transfusional support.
The American Society of Clinical Oncology (ASCO) and
the American Society of Hematology (ASH) ﬁrst
published a joint evidence-based clinical practice
guideline for the use of ESAs in adults with cancer and
anemia in 2002,8 with updates in 20079 and 2010.10
Since the 2010 update, additional information has
emerged about the safety and efﬁcacy of ESAs in
patients with metastatic breast cancer and about the role
of iron in conjunction with ESAs. Treatment options have
also expandedwith the 2018 FDAapproval of a biosimilar
of epoetin alfa, warranting a guideline update.11
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THE BOTTOM LINE
Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical
Practice Guideline Update
Guideline Question
When and how should erythropoiesis-stimulating agents (ESAs) be used to manage anemia in adults with
cancer?
Target Population
Adults with cancer and anemia.
Target Audience
Oncologists, hematologists, oncology nurses, oncology pharmacists, and other health care professionals who care
for patients with cancer, and patients with cancer.
Methods
An Expert Panel was convened to update clinical practice guideline recommendations based on a systematic review
of the medical literature.
Recommendations
Clinical Question 1
To reduce the need for RBC transfusions, should ESAs be offered to patients who have chemotherapy-associated
anemia?
Recommendation 1.1. Depending on clinical circumstances, ESAs may be offered to patients with
chemotherapy-associated anemia whose cancer treatment is not curative in intent and whose hemoglobin
(HgB) has declined to, 10 g/dL. RBC transfusion is also an option, depending on the severity of the anemia
or clinical circumstances (Type: evidence based; Evidence quality: high; Strength of recommendation:
strong).
Recommendation 1.2. ESAs should not be offered to patients with chemotherapy-associated anemia whose
cancer treatment is curative in intent (Type: evidence based; Evidence quality: intermediate; Strength of
recommendation: strong).
Clinical Question 2
To reduce the need for RBC transfusions, should ESAs be offered to anemic patients with cancer who are not
receiving concurrent myelosuppressive chemotherapy?
Recommendation 2.1. ESAs should not be offered to most patients with nonchemotherapy-associated
anemia (Type: informal consensus; Evidence quality: low; Strength of recommendation: strong).
Recommendation 2.2. ESAs may be offered to patients with lower risk myelodysplastic syndromes and a serum
erythropoietin level # 500 IU/L (Type: evidence based; Evidence quality: intermediate; Strength of rec-
ommendation: moderate).
Clinical Question 3
What special considerations apply to adult patients with nonmyeloid hematologic malignancies who are receiving
concurrent myelosuppressive chemotherapy?
Recommendation 3. In patients with myeloma, non-Hodgkin lymphoma, or chronic lymphocytic leukemia,
clinicians should observe the hematologic response to cancer treatment before considering an ESA.
Particular caution should be exercised in the use of ESAs concomitant with treatment strategies and diseases
where risk of thromboembolic complications is increased (see Recommendations 4 and 6). In all cases,
blood transfusion is a treatment option that should be considered (Type: informal consensus; Evidence
quality: low; Strength of recommendation: moderate).
Clinical Question 4
What examinations and diagnostic tests should be performed before making a decision about using an ESA to
identify patients who are likely to beneﬁt from an ESA?
(continued on following page)
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THE BOTTOM LINE (CONTINUED)
Recommendation 4. Before offering an ESA, clinicians should conduct an appropriate history, physical ex-
amination, and diagnostic tests to identify alternative causes of anemia aside from chemotherapy or an
underlying hematopoietic malignancy. Such causes should be appropriately addressed before considering
the use of ESAs. Suggested baseline investigations are listed in Table 1 (Type: informal consensus; Evidence
quality: intermediate; Strength of recommendation: strong).
Clinical Question 5
Among adult patients who receive an ESA for chemotherapy-associated anemia, do darbepoetin, epoetin beta and
alfa originator, and currently available biosimilars of epoetin alfa differ with respect to safety or efﬁcacy?
Recommendation 5. The Expert Panel considers epoetin beta and alfa, darbepoetin, and biosimilar epoetin alfa
to be equivalent with respect to effectiveness and safety (Type: informal consensus; Evidence quality:
intermediate; Strength of recommendation: moderate).
Clinical Question 6
Do ESAs increase the risk of thromboembolism?
Recommendation 6. ESAs increase the risk of thromboembolism, and clinicians should carefully weigh the
risks of thromboembolism and use caution and clinical judgment when considering use of these agents
(Type: evidence based; Evidence quality: high; Strength of recommendation: strong).
Clinical Question 7
Among adult patients who will receive an ESA for chemotherapy-associated anemia, what are recommendations for
ESA dosing and dose modiﬁcations?
Recommendation 7. It is recommended that starting and modifying doses of ESAs follow FDA guidelines (see
Table 2 for speciﬁc dosing information; Type: informal consensus; Evidence quality: intermediate; Strength
of recommendation: moderate).
Clinical Question 8
Among adult patients who will receive an ESA for chemotherapy-associated anemia, what is the recommended
target HgB level?
Recommendation 8. HgB may be increased to the lowest concentration needed to avoid or reduce the need for
RBC transfusions, which may vary by patient and condition (Type: informal consensus; Evidence quality:
intermediate; Strength of recommendation: moderate).
Clinical Question 9
Among adult patients with chemotherapy-associated anemia who do not respond to ESA therapy (, 1 to 2 g/dL
increase in HgB or no decrease in transfusion requirements), does continuation of ESA therapy beyond 6 to 8 weeks
provide a beneﬁt?
Recommendation 9. ESAs should be discontinued in patients who do not respond within 6 to 8 weeks. Patients
who do not respond to ESA treatment should be reevaluated for underlying tumor progression, iron de-
ﬁciency, or other etiologies for anemia (Type: informal consensus; Evidence quality: intermediate; Strength
of recommendation: strong).
Clinical Question 10
Among adult patients with chemotherapy-associated anemia, does iron supplementation concurrent with an ESA
reduce transfusion requirements?
Recommendation 10. Iron replacement may be used to improve HgB response and reduce RBC transfusions
for patients receiving ESA with or without iron deﬁciency. Baseline and periodic monitoring of iron, total iron-
binding capacity, transferrin saturation, or ferritin levels is recommended (Type: evidence based; Evidence
quality: intermediate; Strength of recommendation: weak).
(continued on following page)
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GUIDELINE QUESTIONS
This clinical practice guideline addresses 10 clinical ques-
tions: (1) To reduce the need for RBC transfusions, should
ESAs be offered to patients who have chemotherapy-
associated anemia? (2) To reduce the need for RBC
transfusions, should ESAs be offered to anemic patients
with cancer who are not receiving concurrent myelosup-
pressive chemotherapy? (3) What special considerations
apply to adult patients with nonmyeloid hematologic ma-
lignancies who are receiving concurrent myelosuppressive
chemotherapy? (4) What examinations and diagnostic tests
should be performed before making a decision about using
an ESA to identify patients who are likely to beneﬁt from an
ESA? (5) Among adult patients who receive an ESA for
chemotherapy-associated anemia, do darbepoetin, epoetin
beta and alfa originator, and currently available biosimilars
of epoetin alfa differ with respect to safety or efﬁcacy? (6) Do
ESAs increase the risk of thromboembolism? (7) Among
adult patients who will receive an ESA for chemotherapy-
associated anemia, what are recommendations for ESA
dosing and dose modiﬁcations? (8) Among adult patients
who will receive an ESA for chemotherapy-associated ane-
mia, what is the recommended target HgB level? (9) Among
adult patients with chemotherapy-associated anemia who
do not respond to ESA therapy (, 1 to 2 g/dL increase in
HgB or no decrease in transfusion requirements), does
continuation of ESA therapy beyond 6 to 8 weeks provide a
beneﬁt? (10) Among adult patients with chemotherapy-
associated anemia, does iron supplementation concur-
rent with an ESA reduce transfusion requirements?
METHODS
Guideline Update Process
This systematic review-based guideline was developed by a
multidisciplinary Expert Panel (Appendix Table A1, online
only), which included a patient representative and an ASCO
guidelines staff member with health research method-
ology expertise. The Expert Panel met via webinar and
corresponded through e-mail. Based upon the con-
sideration of the evidence, the authors were asked to
contribute to the development of the guideline, provide
critical review, and ﬁnalize the guideline recommendations.
The guideline recommendations were sent for an open
comment period of 2 weeks, allowing the public to review
and comment on the recommendations after submitting a
conﬁdentiality agreement. These comments were taken into
consideration while ﬁnalizing the recommendations. Mem-
bers of the Expert Panel were responsible for reviewing and
approving the penultimate version of guideline, which was
then circulated for external review and submitted to the
Journal of Clinical Oncology (JCO) for editorial review and
consideration for publication. All ASCO guidelines are ulti-
mately reviewed and approved by the Expert Panel and the
ASCO Clinical Practice Guidelines Committee prior to pub-
lication. The guideline was also reviewed and approved by
the ASH Guideline Oversight Subcommittee, the ASH
Committee on Quality, and ASH Ofﬁcers. All funding for the
administration of the project was provided by ASCO.
The recommendations were developed using a systematic
review of the literature from January 31, 2010, through May
14, 2018, and clinical experience. For all questions except
the question on biosimilars, PubMed and the Cochrane Li-
brary were searched for randomized controlled trials (RCTs)
and meta-analyses of RCTs. Publications were included if
they assessed the efﬁcacy and safety of ESAs in patients with
cancer and included at least 50 patients per arm. For the
question on biosimilars, PubMed and the Cochrane Library
were searched for RCTs and meta-analyses of RCTs in pa-
tients with cancer or chronic kidney disease (CKD), or cohort
studies in patients with cancer. For all questions, primary
outcomes of interest were mortality, frequency of RBC
transfusion, thromboembolic risk, and progression-free sur-
vival. In the case of biosimilars, HgB response and immu-
nogenicity were additional outcomes of interest. Secondary
outcomes included quality of life, fatigue, and overall survival.
Search terms are provided in the Data Supplement.
Articles were excluded from the systematic review if they
were (1) meeting abstracts not subsequently published in
peer-reviewed journals; (2) editorials, commentaries, let-
ters, news articles, case reports, or narrative reviews; (3)
published in a non-English language; or (4) an RCT that
was analyzed in an included meta-analysis.
The updated search was guided by the “signals”12 ap-
proach that is designed to identify only new, potentially
THE BOTTOM LINE (CONTINUED)
Additional Resources
More information, including a Data Supplement with additional evidence tables, slide sets, and clinical tools and
resources, is available at www.asco.org/supportive-care-guidelines. Patient information is available at www.cancer.
net. The Methodology Manual (available at www.asco.org/guideline-methodology) provides additional information
about the methods used to develop this guideline update.
ASCO and the ASH believe that cancer clinical trials are vital to inform medical decisions and improve cancer care,
and that all patients should have the opportunity to participate.
4 © 2019 by American Society of Clinical Oncology
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practice-changing data—signals—that might translate into
revised practice recommendations. The approach relies on
targeted routine literature searching and the expertise of
Expert Panel members to help identify potential signals.
Before publication, a review of the guideline’s feasibility for
implementation was also conducted. Ratings for the type
and strength of the recommendation and the quality of
evidence are provided with each recommendation. The
Methodology Manual (available at www.asco.org/guideline-
methodology) provides additional information about the
methods used to develop this guideline update.
The Expert Panel and guidelines staff will work with co-chairs
to keep abreast of the need for any substantive updates to
the guideline. Based on formal review of the emerging lit-
erature, ASCO and ASH will determine the need to update.
This is themost recent information as of the publication date.
Guideline Disclaimer
The Clinical Practice Guidelines and other guidance
published herein are provided by the American Society of
Clinical Oncology, Inc. (ASCO) and the American Society of
Hematology (ASH) to assist providers in clinical decision
making. The information herein should not be relied upon
as being complete or accurate, nor should it be considered
as inclusive of all proper treatments or methods of care or as
a statement of the standard of care. With the rapid de-
velopment of scientiﬁc knowledge, new evidence may
emerge between the time information is developed and
when it is published or read. The information is not con-
tinually updated and may not reﬂect the most recent evi-
dence. The information addresses only the topics
speciﬁcally identiﬁed therein and is not applicable to other
interventions, diseases, or stages of diseases. This in-
formation does not mandate any particular course of
medical care. Further, the information is not intended to
substitute for the independent professional judgment of the
treating provider, as the information does not account for
individual variation among patients. Recommendations
reﬂect high, moderate, or low conﬁdence that the rec-
ommendation reﬂects the net effect of a given course of
action. The use of words like “must,” “must not,” “should,”
and “should not” indicates that a course of action is rec-
ommended or not recommended for either most or many
patients, but there is latitude for the treating physician to
select other courses of action in individual cases. In all cases,
the selected course of action should be considered by the
treating provider in the context of treating the individual
patient. Use of the information is voluntary. ASCO and ASH
provide this information on an “as is” basis and makes no
warranty, express or implied, regarding the information.
ASCO and ASH speciﬁcally disclaim any warranties of
merchantability or ﬁtness for a particular use or purpose.
ASCO and ASH assume no responsibility for any injury or
damage to persons or property arising out of or related to any
use of this information, or for any errors or omissions.
Guideline and Conﬂicts of Interest
The Expert Panel was assembled in accordance with ASCO’s
Conﬂict of Interest Policy Implementation for Clinical Practice
Guidelines (“Policy,” found at http://www.asco.org/rwc), with
additional policies mutually agreed upon with ASH. All
members of the Expert Panel completed ASCO’s disclosure
form, which requires disclosure of ﬁnancial and other
interests, including relationships with commercial entities
that are reasonably likely to experience direct regulatory or
commercial impact as a result of promulgation of the
guideline. Categories for disclosure include employment;
leadership; stock or other ownership; honoraria, consul-
ting or advisory role; speaker’s bureau; research funding;
patents, royalties, other intellectual property; expert tes-
timony; travel, accommodations, expenses; and other
relationships. In accordance with the Policy, the majority
of the members of the Expert Panel did not disclose any
relationships constituting a conﬂict under the Policy.
RESULTS
The primary literature review included 15 meta-analyses of
RCTs1,2,13-25 and two RCTs.6,26 Three meta-analyses15,20,22
addressed the addition of iron to an ESA. The remaining 12
meta-analyses1,2,13,14,16-19,21,23-25 addressed ESA versus
control (placebo or best standard therapy). The quality of
the meta-analyses varied based on AMSTAR2 criteria, such
as assessment and discussion of bias and heterogeneity.
The two RCTs consisted of a large phase III RCT in met-
astatic breast cancer6 and a smaller trial in myelodysplastic
syndrome (MDS).26 Evidence tables and quality assess-
ments for included meta-analyses and RCTs are provided
in the Data Supplement.
For biosimilars, both of the includedmeta-analyses27,28 and
one29 of the two RCTs29,30 involved patients with CKD. The
only RCT in patients with cancer30 had a high likelihood of
bias based on inadequate sample size, lack of an intent-to-
treat analysis, and industry funding and authorship. The
quality of the four included cohort studies of biosimilars31-34
in patients with cancer was not formally assessed.
RECOMMENDATIONS
CLINICAL QUESTION 1
To reduce the need for RBC transfusions, should ESAs be
offered to patients who have chemotherapy-associated anemia?
Recommendation 1.1
Depending on clinical circumstances, ESAs may be offered
to patients with chemotherapy-associated anemia whose
cancer treatment is not curative in intent and whose HgB
has declined to , 10 g/dL. RBC transfusion is also an
option, depending on the severity of the anemia or clinical
circumstances (Type: evidence based; Evidence quality:
high; Strength of recommendation: strong).
Journal of Clinical Oncology 5
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Recommendation 1.2
ESAs should not be offered to patients with chemotherapy-
associated anemia whose cancer treatment is curative in
intent (Type: evidence based; Evidence quality: intermediate;
Strength of recommendation: strong).
Literature review update and analysis. In the 2010 guide-
line, use of ESAs in relation to intent of treatment (curative v
palliative) was addressed in a Special Note. In this update,
the Expert Panel chose to address treatment intent in a
recommendation.
The results of the updated systematic review conﬁrmed that
ESAs reduce the risk for RBC transfusion1,2,6,18,19,21,24 and
increase the risk of thromboembolism.1,2,6,16,19,25 ESAs
were associated with an increased risk of on-study mortality
in some1,2 but not all18,24 meta-analyses. The two meta-
analyses that reported nonsigniﬁcant associations with on-
study mortality focused on speciﬁc subgroups of patients
deﬁned by cancer type24 or HgB level18 and included rela-
tively small sample sizes. Seven meta-analyses1,2,13,17,19,21,24
and an RCT6 reported on overall survival, with only one
publication13 reporting a statistically signiﬁcant associa-
tion with ESA use. Aapro et al13 reported an increased risk
of death in ESA users (odds ratio, 1.20; 95% CI, 1.03 to
1.40) based on nine RCTs in patients with breast cancer.
Meta-analyses consistently reported statistically signiﬁ-
cant reductions in fatigue with ESA use,1,2,14,23 but the
effect sizes were small and unlikely to be clinically
important.35
Little information about treatment intent is available from
published studies, but one RCT6 in the updated literature
review restricted to patients with metastatic breast cancer
and one meta-analysis1 developed a decision model that
incorporated intent of treatment. The 2013 Agency for
Healthcare Research and Quality meta-analyses by Grant
et al1 developed decision models for patients treated with
curative or noncurative intent. The models suggest that
ESAs increase quality-adjusted life-years but decrease life-
years in both the curative and noncurative setting. The
2016 noninferiority trial by Leyland-Jones et al6 compared
epoetin alfa to best supportive care in 2,098 patients
with metastatic breast cancer. The primary outcome of
interest—progression-free survival based on investigator-
determined progressive disease—did not meet non-
inferiority criteria (hazard ratio [HR] 1.09; 95% CI, 0.99 to
1.20; prespeciﬁed noninferiority margin was 1.15). In their
conclusion, the investigators state, “In light of these study
results, RBC transfusion should be the preferred approach
for the management of anemia during ﬁrst- or second-line
chemotherapy for metastatic breast cancer. If EPO is to be
used in the more advanced settings of metastatic breast
cancer, this should be done with caution and based on
careful risk-beneﬁt assessment.”6 (p1205)
Subgroup analyses of ESA efﬁcacy and safety by baseline
HgB were provided by four meta-analyses1,2,14,21 and one
RCT.6 In the 2013 Agency for Healthcare Research and
Quality meta-analysis by Grant et al,1 patients who initiated
ESA use at a lower HgB level (# 10 g/dL) had a greater
reduction in likelihood of RBC transfusion than patients
who initiated ESA use at a higher baseline HgB level
(relative risk, 0.46; 95% CI, 0.41 to 0.49, for patients with
lower HgB at ESA initiation, compared with relative risk,
0.71; 95% CI, 0.65 to 0.79, for patients with higher HgB at
ESA initiation; P , .01 for interaction). The effects of ESA
use on on-study mortality and overall survival did not differ
signiﬁcantly by baseline HgB level. In the 2012 Cochrane
review by Tonia et al,2 three levels of baseline HgB were
analyzed:# 10 g/dL, 10 to 12 g/dL, and. 12 g/dL. Patients
with a baseline HgB level of 10 to 12 g/dL had the greatest
reduction in risk of RBC transfusion with ESA use. In the
remaining two meta-analyses, baseline HgB did not sig-
niﬁcantly modify the association between ESA use and
fatigue14 or overall survival.21 In the 2016 RCT by Leyland-
Jones et al,6 the HRs for progression-free survival were
similar in patients with lower and higher baseline HgB levels
(HR, 1.11; 95% CI, 0.92 to 1.33, for patients with baseline
HgB , 10 g/dL; HR, 1.08; 95% CI, 0.96 to 1.21, for pa-
tients with baseline HgB $ 10 g/dL); a test for interaction
was not reported, but 95% CIs are widely overlapping.
Clinical interpretation. As of the date of this publication, the
FDA-approved labels state that ESAs are indicated for the
treatment of anemia due to concomitant, myelosuppressive
chemotherapy that is expected to continue for at least 2
additional months after ESA initiation. The labels state that
ESAs are not indicated for use in patients with cancer
receiving myelosuppressive chemotherapy in whom the
anemia can be managed by transfusion. A boxed warning
includes several additional cautionary notes for use in
cancer, including a statement that ESAs are not indicated
for patients receiving myelosuppressive chemotherapy
when the anticipated outcome is cure.
Unfortunately, it cannot be determined from the available
evidence whether any particular group of potential ESA
recipients has a greater or lesser risk of harm than other
patients with chemotherapy-induced anemia. The mech-
anisms of harm are also unclear. The FDA-approved label’s
distinction between patients being treated with curative
versus palliative intent may assist clinicians as they com-
pare and discuss with patients the risk-to-beneﬁt ratios of
an ESA versus RBC transfusions. The decision to limit the
indication for ESAs to patients undergoing chemotherapy
for palliation (treatment intent) is not based on direct
comparative analyses of data from clinical trials of ESA
treatment based on the intent of any particular regimen
used. Rather, it is based on the known risks, such as in-
creased risk for thromboembolic events and short-term
mortality and decreased overall survival. These increased
risks have been observed across different patient groups.6,36
With currently available evidence, it is not possible to de-
termine a patient group that could safely use ESAs.
6 © 2019 by American Society of Clinical Oncology
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Note also that determining the goal of treatment requires
clinical judgment. Examples of diseases for which the
treatment goal should generally be considered curative
include (among others) testicular cancer, ﬁrst-line therapy
of Hodgkin disease, and early-stage solid tumors treated
with adjuvant chemotherapy (eg, breast, colon, early lung).
The Expert Panel acknowledges the FDA’s assessment that
the reported beneﬁts of ESAs may be outweighed by risks
considered unacceptable in patients who might otherwise
expect cure or moderate to long survival from their che-
motherapy. Clinicians are urged to exercise caution in
considering ESA use in patients with malignancy being
treated with curative intent. The Expert Panel stresses the
importance of including a detailed discussion between
health care providers and their patients about the potential
harms and beneﬁts of ESA therapy.
FDA-approved labeling for each ESA also states, “Initiate…in
patients on cancer chemotherapy only if the hemoglobin is
less than 10 g/dL.” The Expert Panel accepts that, although
evidence is lacking to establish an optimal HgB threshold
for starting ESA therapy, it is clinically prudent to wait until
HgB concentration decreases to less than 10 g/dL. How-
ever, the Expert Panel acknowledges that rare clinical
circumstances (such as severe pulmonary or cardiovas-
cular comorbidities) may warrant careful consideration of
ESA use when HgB levels are $ 10 g/dL.
In rare circumstances, patients with cancer and renal in-
sufﬁciency may have concurrent indications for the use of
ESAs. Clinicians should also consider guidelines on ESA
use for CKD-related anemia under these circumstances.
CLINICAL QUESTION 2
To reduce the need for RBC transfusions, should ESAs be
offered to anemic patients with cancer who are not re-
ceiving concurrent myelosuppressive chemotherapy?
Recommendation 2.1
ESAs should not be offered to most patients with
nonchemotherapy-associated anemia (Type: informal con-
sensus; Evidence quality: low; Strength of recommendation:
strong).
Recommendation 2.2
ESAs may be offered to patients with lower-risk MDSs and a
serum erythropoietin level # 500 IU/L (Type: evidence
based; Evidence quality: intermediate; Strength of recom-
mendation: moderate).
Literature review update and analysis. The recommenda-
tion against ESA use in patients who are not receiving
concomitant myelosuppressive chemotherapy (with the
exception noted in Recommendation 2.2) has been
reworded, but the intent is the same as in 2010. Rec-
ommendation 2.2 has been revised to specify serum
erythropoietin levels at which an ESA may be appropriate
in MDS.
Two meta-analyses in the updated literature review pre-
sented subgroup results by cancer treatment.2,14 Neither
provided evidence that would support a change to the
Recommendation 2.1. In a 2014 meta-analysis of ESAs
and fatigue,14 a beneﬁt of ESAs was numerically greatest
among patients treated with chemotherapy, although the
test for interaction by type of cancer treatment was not
statistically signiﬁcant (P = .22). In a 2012 meta-analysis,2
type of cancer treatment did not qualify for inclusion in
multivariate models of ESA safety and efﬁcacy.
In patients with MDS, one RCT evaluated the addition
of epoetin beta to lenalidomide in 131 patients with
RBC transfusion-dependent, low, or intermediate-1 risk
(according to the International Prognostic Scoring System),
ESA refractory, nondel(5q) MDS.26 The combination of
lenalidomide and epoetin beta increased the frequency of
erythroid response relative to lenalidomide alone (39% v
23%; P = .04), but did not signiﬁcantly affect duration of
erythroid response (15 v 18 months; P = .64) or likelihood
of transfusion independence (24% v 14%; P = .13). In
subgroup analyses, patients with lower baseline serum
erythropoietin levels had higher rates of erythroid response.
Clinical interpretation. There is no evidence that the rel-
ative effects of ESAs to reduce the risk for RBC transfusions
differ in patients with and without myelosuppressive che-
motherapy. However, according to current licensing, ESAs
are only indicated in patients who are anemic from con-
current myelosuppressive chemotherapy and not in pa-
tients with cancer who are not receiving concurrent
myelosuppressive chemotherapy.
In patients with MDS, some studies suggest that patients
with elevated baseline erythropoietin levels (. 500 IU/L)
are unlikely to respond to ESA therapy.37 Furthermore, a
recent study has suggested that an even lower baseline
erythropoietin level (, 200 IU/L) is associated with a
better HgB response.38 ESAs should be avoided in pa-
tients with MDS with elevated baseline erythropoietin
levels (. 500 IU/L). Lower pretreatment RBC transfusion
dependence (, 2 units per month) has also been asso-
ciated with a higher likelihood of ESA response in patients
with MDS.39 Among the potential beneﬁts of ESA therapy
in patients with MDS is avoidance of secondary hemo-
chromatosis, particularly for lower risk patients who may
have years of survival.
CLINICAL QUESTION 3
What special considerations apply to adult patients with
nonmyeloid hematologic malignancies who are receiving
concurrent myelosuppressive chemotherapy?
Recommendation 3
In patients with myeloma, non-Hodgkin lymphoma, or
chronic lymphocytic leukemia, clinicians should ob-
serve the hematologic response to cancer treatment be-
fore considering an ESA. Particular caution should be
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exercised in the use of ESAs concomitant with treatment
strategies and diseases where risk of thromboembolic
complications is increased (see Recommendations 4 and
6). In all cases, blood transfusion is a treatment option
that should be considered (Type: informal consensus;
Evidence quality: low; Strength of recommendation:
moderate).
Literature review update and analysis. The 2012 Cochrane
review by Tonia et al2 conducted subgroup analyses by
cancer type and provided results for mortality, RBC
transfusion, thromboembolism, and fatigue. Interactions
by cancer type were nonsigniﬁcant except for RBC
transfusions: the reduction in risk of RBC transfusion with
ESA use was greatest among patients with solid tumors.
Other meta-analyses also evaluated subgroups of pa-
tients with hematologic malignancies, but only in relation
to a single outcome: overall survival (nonsigniﬁcantly
associated with ESA use based on a single study of 60
patients with lymphoma),21 thromboembolism (increased
risk with ESA use),16 or fatigue (decreased risk with
ESA use).14
Clinical interpretation. The FDA label now limits the in-
dication for ESA use to patients receiving chemotherapy
for noncurative intent. In patients with nonmyeloid he-
matologic malignancies, who are being treated with pal-
liative intent and in whom a short survival can be
reasonably expected, use of ESAs can be considered if
anemia does not improve with treatment of the underlying
malignancy and cannot be supported with transfusions
due to logistical or personal factors or preferences.
However, given the recent advances in the treatment of
these diseases that have resulted in signiﬁcant im-
provements in survival, very careful consideration should
be given to the categorization of the treatment intent.
Evaluation of individual cases must be based on the intent
of treatment and the life expectancy for each patient.
Because these malignancies recur in most patients but
multiple treatments are currently available for this situa-
tion, determining the treatment intent and the expected
survival requires clinical judgment of an individual pa-
tient’s circumstances. Additionally, the risks of other
complications, in particular, thromboembolic events,
must be taken into account as many agents can increase
the risk of this complication (eg, immunomodulatory drugs
in multiple myeloma). Finally, it should be noted that there
is little to no information regarding the risks and beneﬁts of
the concurrent use of ESAs and newer agents, such as
monoclonal antibodies and targeted and cellular thera-
pies, and therefore, no recommendations can be issued in
this regard.
CLINICAL QUESTION 4
What examinations and diagnostic tests should be per-
formed before making a decision about using an ESA to
identify patients who are likely to beneﬁt from an ESA?
Recommendation 4
Before offering an ESA, clinicians should conduct an ap-
propriate history, physical examination, and diagnostic
tests to identify alternative causes of anemia aside from
chemotherapy or an underlying hematopoietic malignancy.
Such causes should be appropriately addressed before
considering the use of ESAs. Suggested baseline in-
vestigations are listed in Table 1 (Type: informal consensus;
Evidence quality: intermediate; Strength of recommenda-
tion: strong).
Literature review update and analysis. No new eligible
publications were identiﬁed by the updated literature review.
Clinical interpretation. Given the risks associated with the
use of ESAs, it is of the utmost importance to assess the
need for and the risks of their use. Therefore, changes to
the previous recommendations include clariﬁcation of the
investigations suggested in the work-up of anemia prior to
considering the use of ESAs since addressing reversible
causes of anemia is the preferred initial approach. Addi-
tionally, given the increased risk of thromboembolism,
evaluating thrombotic risk is very important. This is
addressed in Clinical Question 6.
CLINICAL QUESTION 5
Among adult patients who receive an ESA for chemotherapy-
associated anemia, do darbepoetin, epoetin beta and alfa
originator, and currently available biosimilars of epoetin
alfa differ with respect to safety or efﬁcacy?
Recommendation 5
The Expert Panel considers epoetin beta and alfa, dar-
bepoetin, and biosimilar epoetin alfa to be equivalent with
respect to effectiveness and safety (Type: informal consen-
sus; Evidence quality: intermediate; Strength of recom-
mendation: moderate).
Literature review update and analysis. Three meta-
analyses conducted subgroup analyses by type of ESA
(epoetin v darbepoetin).1,2,16 The two agents showed similar
safety and efﬁcacy. One exception to this was reported in
the 2012 Cochrane review by Tonia et al.2 Epoetin was
associated with a larger improvement in fatigue than dar-
bepoetin, but these results may have been confounded by
three darbepoetin trials without anticancer treatment.
The systematic review of biosimilar ESAs included two
meta-analyses27,28 and one RCT29 in patients with CKD,
and one RCT30 and three cohort studies31-33 in patients with
cancer. In a 2017 meta-analysis of RCTs in CKD, Amato
et al27 reported that efﬁcacy and safety outcomes did not
differ signiﬁcantly between patients treated with epoetin
alfa originator or biosimilar but described the quality of
evidence as low to very low. A 2017Cochrane review byHahn
et al28 focused on short-acting ESAs in predialysis patients.
The review identiﬁed one trial of HX575 (a biosimilar of
epoetin alfa), but results were not available; the trial was
stopped early when two patients receiving HX575 developed
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antibodies to epoetin and pure red cell aplasia. HX575 was
also evaluated in a 2017RCT byWeir et al.29 The trial enrolled
adults with end-stage renal disease who were on dialysis and
had been receiving stable doses of epoetin alfa. Patients were
randomly assigned to continue epoetin alfa or to receive
HX575. The two agents were similarly effective at maintaining
stable HgB levels. Binding anti-erythropoietin antibodies
developed in six patients (2.8%) in the HX575 arm and one
patient (0.5%) in the epoetin alfa arm, but no patients de-
veloped neutralizing anti-erythropoietin antibodies.
The single RCT in patients with cancer was small: 60
patients assigned to HX575 and 34 assigned to epoetin alfa
were included in the analysis.30 All patients had solid
tumors and chemotherapy-associated anemia. HX575
appeared to be effective with respect to HgB response, but
the possibility of bias in this study limits ﬁrm conclusions. A
large retrospective population-based cohort study in Italy
evaluated more than 13,000 new ESA users, 8161 with
CKD and 5,309 with cancer.33 A biosimilar epoetin alfa had
been used by 154 (1.9%) of the patients with CKD and 453
(8.5%) of the patients with cancer. Biosimilar and originator
epoetin alfa had similar safety and efﬁcacy in both CKD and
cancer with one exception: among patients with cancer,
biosimilar epoetin alfa was associated with lower overall
mortality than the originator (HR, 0.82; 95% CI, 0.70 to
0.97), but this ﬁnding is not conclusive because residual
confounding could not be excluded since more patients in
the originator group died of cancer activity. A retrospective
study of patients with MDS and refractory anemia evaluated
46 patients treated with biosimilar epoetin alfa and 46
patients with originator epoetin alfa. Median time to reach
an HgB level . 12 g/dL was 10.5 weeks (range, 3 to
16 weeks) among patients treated with the biosimilar and
12 weeks (range, 4 to 18 weeks) among patients treated
with the originator product.31 Finally, a retrospective study of
419 patients with cancer compared biosimilar epoetin alfa
with darbepoetin alfa.32 Mean HgB increase was similar in
the two groups. Blood transfusions were received by 8% of
patients treated with biosimilar epoetin alfa and 14% of
patients treatedwith darbepoetin alfa (P = .04). These results
were conﬁrmed in another Italian retrospective cohort study,
which did not ﬁnd a difference in HgB response among new
users of either biosimilars or reference product of epoetin
alfa or other ESAs in either CKD or patients with cancer
during the ﬁrst 3 months of treatment.34
Clinical interpretation. Based on limited evidence, it seems
that compared with the originator, biosimilars of epoetin alfa
are safe and effective. However, the evidence is of moderate
to low quality, and this is derived from studies in patients with
cancer and CKD. Biosimilars have been available in Europe
for over 10 years, and no major concerns have arisen. In the
United States, these agents are more recent. Users should
review pertinent approvals and indications as per their local
regulatory authorities. Ultimately, the choice of a particular
agent will depend on cost, availability, convenience, and
personal considerations or preference.40,41
CLINICAL QUESTION 6
Do ESAs increase the risk of thromboembolism?
Recommendation 6
ESAs increase the risk of thromboembolism, and clinicians
should carefully weigh the risks of thromboembolism and
use caution and clinical judgment when considering use of
these agents (Type: evidence based; Evidence quality:
high; Strength of recommendation: strong).
Literature review update and analysis. The publications in
the updated review consistently report an increased risk of
thromboembolism in ESA-treated patients.1,2,6,16,19,25 This
increased thromboembolic risk with ESA use was observed
across categories of baseline HgB,2 type of cancer,2,16,25
and type of ESA.1,2,16
Clinical interpretation. Meta-analyses and individual
RCTs consistently report a 50%1,2 to 75%16,25 increased
risk of thromboembolism and vascular arterial events
among patients receiving ESA therapy. The Expert Panel
continues to urge caution in the use of ESAs for patients
judged to be at increased risk for venous thromboembolism.
Several risk scores for predicting venous thromboembolism
have been developed; these are discussed in more detail in
TABLE 1. Suggested Baseline Investigations for Anemia in Patients With Cancer Receiving Chemotherapy
Suggested Investigation
Thorough drug exposure history
Review of a peripheral blood smear*
Analyses, where indicated, for iron, total iron-binding capacity, transferrin saturation, ferritin, folate, vitamin B12, or hemoglobinopathy screening
Assessment of reticulocyte count, occult blood loss, and renal Insufﬁciency
Baseline erythropoietin level
Testing of serum thyroid-stimulating hormone level, where indicated
Investigations may also include direct antiglobulin testing (eg, Coombs test) for patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, or a
history of autoimmune disease
NOTE. Suggestions are based on the consensus of the Expert Panel. This is not intended to be a comprehensive list of investigations.
*And in some cases, a bone marrow examination.
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the ASCO guideline on venous thromboembolism.42 Special
attention should be given to patients with multiple myeloma
who are being treated with thalidomide or lenalidomide and
doxorubicin or corticosteroids since they are at particularly
increased thrombotic risk.43 There are no data from RCTs
investigating concomitant use of anticoagulants or aspirin to
lessen this risk.
CLINICAL QUESTION 7
Among adult patients who will receive an ESA for
chemotherapy-associated anemia, what are recommen-
dations for ESA dosing and dose modiﬁcations?
Recommendation 7
It is recommended that starting and modifying doses of
ESAs follow FDA guidelines (see Table 2 for speciﬁc
dosing information; Type: informal consensus; Evidence
quality: intermediate; Strength of recommendation:
moderate).
Literature review update and analysis. This recommenda-
tion remains unchanged. No publications in the updated
literature review supported nonstandard dosing. Duration
of treatment was analyzed in the 2012 Cochrane review and
did not signiﬁcantly modify the association between ESA
use and on-study mortality, overall survival, likelihood of
RBC transfusion, risk of thromboembolism, or fatigue.2
Clinical interpretation. No new evidence suggests that
outcomes of ESA therapy would be improved by use of an
initial dose or dosemodiﬁcation regimen other than those in
the FDA-approved labels. Note that some aspects of the
labels’ dose increase recommendations have changed
(Table 2).
CLINICAL QUESTION 8
Among adult patients who will receive an ESA for
chemotherapy-associated anemia, what is the recom-
mended target HgB level?
Recommendation 8
HgB may be increased to the lowest concentration needed
to avoid or reduce the need for RBC transfusions, which
may vary by patient and condition (Type: informal consensus;
Evidence quality: intermediate; Strength of recommendation:
moderate).
Literature review update and analysis. No new eligible
publications were identiﬁed by the updated literature
review.
Clinical interpretation. An optimal target HgB concentration
cannot be deﬁnitively determined from the available literature.
Modiﬁcation to reduce the ESA dose is appropriate whenHgB
reaches a level sufﬁcient to avoid transfusion or the increase
exceeds 1 g/dL in any 2-week period to avoid excessive ESA
TABLE 2. ESA Adult Dosing
Dose and
Modiﬁcations Epoetin Alfa* Darbepoetin Alfa
Initial dose† 150 U/kg SC TIW‡ 40,000 U SC weekly§ 2.25 mg/kg SC weekly‡ 500 mg SC
Q3W§
Dose increases Increase dose to 300 U/kg SC TIW if
HgB increases by , 1 g/dL and
remains below 10 g/dL after
4 weeks of therapy
Increase dose to 60,000 U SC weekly
if HgB increases by , 1 g/dL and
remains below 10 g/dL after
4 weeks of therapy
Increase dose to 4.5 mg/kg weekly if
HgB increases by , 1 g/dL and
remains below 10 g/dL after
6 weeks of therapy
N/A
Dose reductions Decrease dose by 25% when HgB reaches a level needed to avoid transfusion
or HgB increases . 1 g/dL in 2 weeks
Decrease dose by 40% when HgB reaches a level
needed to avoid transfusion or HgB increases. 1
g/dL in 2 weeks
Dose withholding If HgB exceeds a level needed to avoid transfusion, restart dose at 25% below
previous dose when HgB approaches a level where transfusion may be
required
If HgB exceeds a level needed to avoid transfusion,
restart dose at 40% below previous dose when
HgB approaches a level where transfusion may be
required
Discontinuek Following completion of chemotherapy course or if no response after 8 weeks
of therapy (measured by HgB levels or continuing need for transfusions)
Following completion of chemotherapy course or if no
response after 8 weeks of therapy (measured by
HgB levels or continuing need for transfusions)
NOTE. Food and Drug Administration product labels were accessed on June 8, 2018, for epoetin (https://www.accessdata.fda.gov/drugsatfda_docs/label/
2017/103234s5363s5366lbl.pdf) and for darbepoetin (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103951s5374lbl.pdf).
Abbreviations: ESA, erythropoiesis-stimulating agent; HgB, hemoglobin; N/A, not applicable; Q3W, every 3 weeks; SC, subcutaneously; TIW, three times
per week.
*Including epoetin alfa-epbx.
†Initiate only if HgB is , 10 g/dL and there is a minimum of two additional months of planned chemotherapy. Use and dosing differ in patients with
myelodysplastic syndromes.
‡Weight-based dose.
§Fixed dose.
kPatients who do not respond to ESA treatment should be re-evaluated for underlying tumor progression, iron deﬁciency, or other etiologies for anemia.
10 © 2019 by American Society of Clinical Oncology
Bohlius et al
Downloaded from ascopubs.org by UNIVERSITAETSSPITAL University BERN on May 9, 2019 from 130.092.180.237
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
exposure, considering the risks of ESAs. Speciﬁc dose-
reduction recommendations are provided in Table 2.
CLINICAL QUESTION 9
Among adult patients with chemotherapy-associated ane-
mia who do not respond to ESA therapy (, 1 to 2 g/dL
increase in HgB or no decrease in transfusion requirements),
does continuation of ESA therapy beyond 6 to 8 weeks
provide a beneﬁt?
Recommendation 9
ESAs should be discontinued in patients who do not re-
spond within 6 to 8 weeks. Patients who do not respond to
ESA treatment should be reevaluated for underlying tumor
progression, iron deﬁciency, or other etiologies for anemia
(Type: informal consensus; Evidence quality: intermediate;
Strength of recommendation: strong).
Literature review update and analysis. No publications in
the updated literature review addressed ESA continuation
in nonresponders.
Clinical interpretation. Given the known harms of ESAs, the
exposure to ESAs should be minimized. In patients who
have received appropriate ESA dosing (see Recommen-
dation 7) and who do not respond, ESAs should be stopped
and not continued.
CLINICAL QUESTION 10
Among adult patients with chemotherapy-associated
anemia, does iron supplementation concurrent with an
ESA reduce transfusion requirements?
Recommendation 10
Iron replacement may be used to improve HgB response
and reduce RBC transfusions for patients receiving ESA
with or without iron deﬁciency. Baseline and periodic
monitoring of iron, total iron-binding capacity, transferrin
saturation, or ferritin levels is recommended (Type: evi-
dence based; Evidence quality: intermediate; Strength of
recommendation: weak).
Literature review update and analysis. The use of supple-
mental iron with an ESA was evaluated in three meta-
analyses.15,20,22 Compared with an ESA alone, a 2016
Cochrane review by Mhaskar et al20 reported that the
combination of an ESA and iron increased the likelihood
of hematopoietic response (RR, 1.17; 95% CI, 1.09 to
1.26) and reduced the likelihood of RBC transfusion (RR,
0.74; 95% CI, 0.60 to 0.92) without signiﬁcantly affecting
risk of thromboembolism (RR, 0.95; 95%CI, 0.54 to 1.65) or
quality of life (standardized mean difference, 0.01; 95%
CI, 20.10 to 0.12). Intravenous (IV) iron provided a greater
beneﬁt than oral iron with respect to mean change in HgB
level (IV iron mean difference, 0.84; 95% CI, 0.21 to 1.46;
P = .009; oral iron mean difference, 0.07; 95% CI,20.19 to
0.34; P = .59; P = .03 for interaction). Route of iron ad-
ministration did not signiﬁcantly modify the association with
hematopoietic response (P = .16). Findings in the two earlier
meta-analyses15,22 were generally similar.
Clinical interpretation. This recommendation changed
from previous versions based on new information published
after the last guideline. The Expert Panel believes that the
use of iron supplementation in all patients receiving ESAs
should be considered, independent of the iron status. This is
based on evidence that iron supplementation reduces the
risk for RBC transfusion. Additionally, in patients with evi-
dence of iron deﬁciency, the cause of the deﬁciency should
be investigated and corrected.
Oral and IV iron formulations are both acceptable options
for iron supplementation. Choice of agents depends on
patient and doctor preferences, formulation availability,
cost, and comorbidities. IV iron preparations have the
advantage of being able to deliver larger amounts of ele-
mental iron in a single application and may also be more
adequate in patients with poor oral intake or absorption
problems. They have the disadvantages of being associated
with more serious systemic reactions and higher costs.
There is some limited evidence that IV iron is superior to oral
iron based on improvement in HgB level. However, the
results were not consistent across all other hematologic
outcomes, and the quality of adverse outcomes reporting
was poor.15,20,22 Safety has been better studied in a sys-
tematic review and meta-analysis in patients with CKD,
which showed no difference in mortality or serious adverse
events in patients receiving intravenous iron, although there
were more episodes of hypotension with IV iron.44
DISCUSSION
Although the use of ESAs reduces the need for transfusions in
anemic patients with cancer receiving chemotherapy, it is
associated with increased complications, including higher
mortality and increased risk of thromboembolic and cardio-
vascular events. For these reasons, the use of ESAs in cancer
is now generally limited to patients who are receiving che-
motherapy with palliative intent and who are expected to have
short survival. The decision about using ESAs must be made
in this context and with a thorough discussion regarding each
patient’s preferences, priorities, values, and spiritual needs.
PATIENT-CLINICIAN COMMUNICATION
Patient counseling regarding the risks and beneﬁts of ESA
therapy is essential to ensure that patients are making
informed decisions. The Expert Panel encourages health
care providers to have an open dialogue with their patients
to help them make informed decisions by considering the
scientiﬁc evidence and weighing their individual risks with
potential harms and beneﬁts of ESA therapy.
In addition to providing a medication guide, health care
providers should discuss the following with patients con-
sidering ESA therapy:
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• When used, the goal of ESA therapy for patients with
chemotherapy-induced anemia is to reduce RBC
transfusion requirements.
• The FDA has indicated that ESAs should not be given
to patients who are being treated for cancer when the
goal is to cure the patients of cancer.
• ESAs have been found to shorten overall survival and/
or speed tumor growth in some patients with cancer.
• ESAs have risks of adverse events, such as throm-
boembolism (ie, blood clots), so individual risk factors
need to be considered.
• ESAs are not recommended for patients with cancer
who are not receiving chemotherapy, except in the
case of patients with lower risk MDS.
For general recommendations and strategies to optimize
patient-clinician communication, see “Patient-Clinician
Communication: American Society of Clinical Oncology
Consensus Guideline.”45
HEALTH DISPARITIES
Although ASCO and ASH clinical practice guidelines repre-
sent expert recommendations on the best practices in dis-
easemanagement to provide the highest level of cancer care,
it is important to note that many patients have limited access
to medical care. Racial and ethnic disparities in health care
contribute signiﬁcantly to this problem in the United States.
Patients with cancer who are members of racial/ethnic mi-
norities suffer disproportionately from comorbidities, experi-
ence more substantial obstacles to receiving care, are more
likely to be uninsured, and are at greater risk of receiving care
of poor quality than other Americans.46-49 Many other patients
lack access to care because of their geographic location and
distance from appropriate treatment facilities. Awareness of
these disparities in access to care should be considered in
the context of this clinical practice guideline, and health care
providers should strive to deliver the highest level of cancer
care to these vulnerable populations.
MULTIPLE CHRONIC CONDITIONS
Creating evidence-based recommendations to inform
treatment of patients with additional chronic conditions, a
situation in which the patient may have two or more such
conditions—referred to as multiple chronic conditions
(MCC)—is challenging. Patients with MCC are a complex
and heterogeneous population, making it difﬁcult to ac-
count for all of the possible permutations to develop speciﬁc
recommendations for care. In addition, the best available
evidence for treating index conditions, such as cancer, is often
from clinical trials whose study selection criteria may exclude
these patients to avoid potential interaction effects or con-
founding of results associated with MCC. As a result, the
reliability of outcome data from these studies may be limited,
thereby creating constraints for expert groups to make recom-
mendations for care in this heterogeneous patient population.
As many patients for whom guideline recommendations
apply present with MCC, any treatment plan needs to
consider the complexity and uncertainty created by the
presence of MCC and highlights the importance of shared
decision making regarding guideline use and imple-
mentation. Therefore, in consideration of recommended
care for the target index condition, clinicians should review
all other chronic conditions present in the patient and take
those conditions into account when formulating the treat-
ment and follow-up plan.
In light of these considerations, practice guidelines should
provide information on how to apply the recommendations
for patients with MCC, perhaps as a qualifying statement
for recommended care. This may mean that some or all of
the recommended care options are modiﬁed or not ap-
plied, as determined by best practice in consideration of
any MCC.
COST IMPLICATIONS
Increasingly, individuals with cancer are required to pay a
larger proportion of their treatment costs through de-
ductibles and coinsurance.50,51 Higher patient out-of-
pocket costs have been shown to be a barrier to initiating
and adhering to recommended cancer treatments.52,53
Discussion of cost can be an important part of shared
decision making.54 Clinicians should discuss with patients
the use of less expensive alternatives when it is practical
and feasible for treatment of the patient’s disease and there
are two or more treatment options that are comparable in
terms of beneﬁts and harms.54
Table 3 shows estimated prices for the available treatment
options addressed in this guideline. Of note, medication
prices may vary markedly, depending on negotiated dis-
counts and rebates.
Patient out-of-pocket costs may vary depending on in-
surance coverage. Coverage may originate in the medical
or pharmacy beneﬁt, which may have different cost-
sharing arrangements. Patients should be aware that
different products may be preferred or covered by their
particular insurance plan. Even with the same insurance
plan, the price may vary between different pharmacies.
When discussing ﬁnancial issues and concerns, patients
should be made aware of any ﬁnancial counseling ser-
vices available to address this complex and heteroge-
neous landscape.54
OPEN COMMENT
The draft recommendations were released to the public for
open comment from August 15, 2018, through August 29,
2018. Response categories of “Agree as written,” “Agree
with suggested modiﬁcations,” and “Disagree. See com-
ments” were captured for every proposed recommendation
with two written comments received. Both respondents ei-
ther agreed or agreed with slight modiﬁcations to the
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recommendations. Expert Panel members reviewed com-
ments from all sources and determined whether to maintain
original draft recommendations, revise with minor language
changes, or consider major recommendation revisions. All
changes were incorporated prior to ASCO Clinical Practice
Guidelines Committee review and approval.
GUIDELINE IMPLEMENTATION
ASCO and ASH guidelines are developed for implementation
across health settings. Barriers to implementation include
the need to increase awareness of the guideline rec-
ommendations among front-line practitioners, survivors
of cancer, and caregivers, as well as the need to provide
adequate services in the face of limited resources. The
guideline Bottom Line Box was designed to facilitate
implementation of recommendations. This guideline will
be distributed widely through the ASCO Practice
Guidelines Implementation Network. ASCO and ASH
guidelines are posted on each organization’s Web site,
and this guideline is jointly published in JCO and Blood
Advances.
LIMITATION OF THE RESEARCH AND FUTURE RESEARCH
There is clear evidence regarding the ability of ESAs to
increase HgB and avoid transfusions. There is also very
consistent evidence of harm associated with their use
across a spectrum of conditions. Since in recent years the
number of new trials is somewhat limited yet consistent with
previous ﬁndings, we believe that rather than focusing on
the occurrence of adverse effects, the most pressing need
for additional research is studies that further clarify the
mechanisms of harm and, particularly, the groups of pa-
tients or circumstances of clinical use that are least as-
sociated with these risks. This information is paramount to
the ability of clinicians to extend the beneﬁt of these drugs
while reducing the risks.
TABLE 3. Estimated Prices of ESAs and Supplemental Iron
Agent
HCPCS Code
Dosage
Medicare Payment
Limit (US$) Initial Dose Regimen Price
ESAs
Darbepoetin alfa
(non-ESRD)
1 mg 3.779 2.25 mg/kg SC Weekly (SC) $1,785.58 per 3-week cycle*
500 mg SC Every 3
weeks (SC)
$1,889.50 per 3-week cycle
Epoetin alfa (non-
ESRD)
1,000 U 13.333 150 U/kg 3 times
weekly
(SC)
$1,259.97 per 3-week cycle*
40,000 U Weekly (SC) $1,599.96 per 3-week cycle
Iron Supplements
Iron dextran 50 mg 13.669 Variable IV $273.38 per 1,000 mg
Ferric gluconate 12.5 mg 2.179 Variable IV $174.32 per 1,000 mg
Iron sucrose 1 mg 0.234 Variable IV $234.00 per 1,000 mg
Ferrous sulfate N/A N/A Variable Oral Available over the counter. Prices at a
sample of online retailers ranged from
$0.01-$0.11 per 325-mg tablet
NOTE. Drug prices were estimated from a third-party payer perspective, based on reimbursement rates from the Centers for Medicare and Medicaid
Services that are widely accepted by providers, computed at themanufacturer’s average sales price. Other treatment-related direct and indirect costs were not
considered, such as diagnostic laboratory tests. Actual treatment costs and reimbursement will vary considerably across regions, payers, institutions, and
practices, as well as over time, and readers should consult current local cost information speciﬁc to their practice setting. Costs were based on Medicare Part
B payment allowance limits effective July 1, 2018 (with no administration fees or other adjustments; Medicare Part B Drug Average Sales Price: https://www.
cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2018ASPFiles.html).
Abbreviations: ESAs, erythropoiesis-stimulating agents; ESRD, end-stage renal disease; HCPCS, Healthcare Common Procedure Coding System; IV,
intravenously; N/A, not applicable; SC, subcutaneously.
*Based on an adult weighing 70 kg.
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